-
Capital, M&A & Industry Strategy1 month agoTelix to buy radiopharma rival ITM for $1.65bn upfront
Telix Pharma has reached a deal to acquire ITM, extending a wave of consolidation in the radiopharma category over the last couple of years.
-
Capital, M&A & Industry Strategy1 month agoTelix to acquire ITM in deal worth up to $2.35bn
The Australian company will pay $1.65bn upfront on a cash-free, debt-free basis. An additional $700m may be payable if ITM-11 meets specified regulatory approval and sales...
-
Capital, M&A & Industry Strategy1 month agoSandoz and mAbxience agree on emicizumab biosimilar partnership
The candidate is in early-stage development and references Hemlibra (emicizumab), a medicine used to treat patients with haemophilia A. The companies said the reference medicine has...
-
Capital, M&A & Industry Strategy1 month agoSTAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work
Under investor pressure, Novo presented its strategy to both grow its obesity franchise and diversify its pipeline.
-
Capital, M&A & Industry Strategy1 month agoAnalysts ‘extremely bullish’ as Telix beams into Novartis’ territory with $1.6B ITM acquisition
Telix has struck a deal to buy ITM Isotope Technologies Munich for $1.65 billion upfront, securing an R&D pipeline led by a rival to Novartis’ Lutathera...
-
Capital, M&A & Industry Strategy1 month ago
Retension and Lilly-backed TRex Bio both set out plans to join biotech IPO stampede
Eli Lilly-backed TRex Bio and hypertension-focused Retension Pharmaceuticals are the latest biotechs to set out plans to go public this year.
-
Capital, M&A & Industry Strategy1 month agoElectra dips after pricing upsized IPO, bucking trend: Public Equity Report
BIOCENTURY | FINANCEELECTRA DIPS AFTER PRICING UPSIZED IPO, BUCKING TREND: PUBLIC EQUITY REPORTPlus: Two more companies line up PIPEs to accompany mergers; Tyra’s follow-on; and more
-
Capital, M&A & Industry Strategy1 month agoThis week in charts: GSK’s China deals, the $300M IPO club and selling the news
The latest installment in BioPharma Dive’s new visualization-focused series features a stock sell-off that confused Wall Street analysts and a closer look at an industry-leading partnership...
-
Capital, M&A & Industry Strategy1 month agoSTAT+: Pharmalittle: We’re reading about licensing deals with China, making drugs in space, and more
The U.S. is working on rules for investing in China that would likely preserve pharma's ability to strike most licensing deals for Chinese drugs
-
Capital, M&A & Industry Strategy1 month agoA national security priority: BIO pushes PAHPA reauthorization in 2026
For decades, Congress has passed legislation to protect Americans from public health emergencies, ranging from national security threats to disease outbreaks and natural disasters, […] The...
LncRNA SBF2-AS1 Worsens Heart Injury After Attack via miR-149-5p/PHLPP2 Axis
Stigmatizing language found in over half of primary care patient records
Research report: The Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
Novartis buys Synnovation’s PI3Kα inhibitors for $3 billion
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
